Literature DB >> 18362284

Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort.

J Zaccai1, C Brayne, I McKeith, F Matthews, P G Ince.   

Abstract

BACKGROUND: It is proposed that alpha-synucleinopathy (AS) initially affects the medulla oblongata and progresses to more rostral brain areas in a hierarchical sequence ("Braak hypothesis"). Predominant involvement of the amygdala is also described. This study examines the applicability of these patterns, and their relationship to Alzheimer disease (AD) pathology, in brains of a population-based donor cohort.
METHODS: Brains donated in two of six Cognitive Function and Ageing Study cohorts (Cambridgeshire and Nottingham) were examined. More than 80% were older than 80 years at death. The respondents were evaluated prospectively in life for cognitive decline and dementia. Immunocytochemistry for tau and alpha-synuclein was carried out in 208 brains to establish Braak stage and the pattern and severity of AS.
RESULTS: Seventy-six brains showed Lewy bodies. Half (51%) conformed to the Braak hypothesis while 17% had pathology in a higher region which was absent in a lower region. A further 29% showed amygdala-predominant pathology. Six brains showed predominant neocortical pathology with minimal pathology in amygdala or substantia nigra. The stage of AD pathology was not associated with particular patterns of AS.
CONCLUSION: alpha-Synucleinopathy (AS) is common in older people, and frequently associated with Alzheimer disease-type pathology. Although half of brains corresponded to the Braak hypothesis, and 29% to amygdala-predominant AS, there were a high proportion of cases which did not fit a staging system. An unexpectedly high proportion with a cortical form of Lewy body disease was identified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362284     DOI: 10.1212/01.wnl.0000306697.48738.b6

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  74 in total

1.  Premotor Parkinson's disease: concepts and definitions.

Authors:  Andrew Siderowf; Anthony E Lang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

Review 2.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

3.  Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.

Authors:  Jon B Toledo; Pallavi Gopal; Kevin Raible; David J Irwin; Johannes Brettschneider; Samantha Sedor; Kayla Waits; Susana Boluda; Murray Grossman; Vivianna M Van Deerlin; Edward B Lee; Steven E Arnold; John E Duda; Howard Hurtig; Virginia M-Y Lee; Charles H Adler; Thomas G Beach; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2015-12-31       Impact factor: 17.088

Review 4.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 5.  Parkinson's disease as a multisystem disorder.

Authors:  Lisa Klingelhoefer; H Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2017-02-02       Impact factor: 3.575

6.  Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?

Authors:  Roberta Frigerio; Hiroshige Fujishiro; Tae-Beom Ahn; Keith A Josephs; Demetrius M Maraganore; Anthony DelleDonne; Joseph E Parisi; Kevin J Klos; Bradley F Boeve; Dennis W Dickson; J Eric Ahlskog
Journal:  Neurobiol Aging       Date:  2009-06-26       Impact factor: 4.673

7.  Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease.

Authors:  Roberta Frigerio; Hiroshige Fujishiro; Demetrius M Maraganore; Kevin J Klos; Anthony DelleDonne; Michael G Heckman; Julia E Crook; Keith A Josephs; Joseph E Parisi; Bradley F Boeve; Dennis W Dickson; J Eric Ahlskog
Journal:  Arch Neurol       Date:  2009-09

Review 8.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

9.  Staging neurological disorders: expressions of cognitive and motor disorder.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2009-11-26       Impact factor: 3.911

10.  Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study.

Authors:  Fiona E Matthews; Carol Brayne; James Lowe; Ian McKeith; Stephen B Wharton; Paul Ince
Journal:  PLoS Med       Date:  2009-11-10       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.